Hereditary disease testing on inferagen
BRCA1/2, hereditary cancer panels, cardiac panels, and ACMG-classified germline variants for clinical reporting.
Clinical context
Hereditary disease testing is where Indian families pay the most attention to genomic reports — and where today's reports fail them most. Patients want to know 'what does this mean for my children?' and 'what should I do next?' — questions that no VCF table answers. inferagen produces a clinician-grade ACMG report and a separate patient-friendly summary in English or the patient's regional language.
What we deliver
On inferagen.
- BRCA1/2 sequencing + large rearrangement detection
- Hereditary cancer panels (Lynch, multi-cancer, pediatric)
- Cardiac panels (cardiomyopathy, arrhythmia, aortic)
- Trio analysis for de novo variant detection
- ACMG 2015 classification with ClinGen specifications
- Family history visualization in the patient summary
Sample report
See exactly what your clinician will receive.
An anonymized PDF for this exact test type — patient summary, clinician summary, and ACMG detail. PII removed.
Download sample reportPricing
Credits per sample.
300–800 credits per sample (~₹6,000 – ₹16,000).
See full pricing & credit consumption →Design-partner programme
First design partners running this in beta — talk to us to be next.
We're onboarding a small group of labs for this test type. Design partners get free credits, white-glove onboarding, and direct input into our roadmap.
Apply to be a design partner →